80 In the COMET study, which compared carvedilol and metoprolol, the diabetics, who comprised 24% of the patients, did not reach statistical significance. 79 , 86 Published RCTs have not conclusively addressed the question of whether a BB class is superior in CHF with comorbid DM, and this remains an area for Phase IV trials.
← all excerpts
A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure.
1
—
—